

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—R Consortium, Inc.**

Notice is hereby given that, on January 4, 2023, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), R Consortium, Inc. (“R Consortium”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Parexel International Corporation, Waltham, MA, has been added as a party to this venture.

Also, RStudio Inc. has changed its name to Posit Software, PBC, Boston, MA.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and R Consortium intends to file additional written notifications disclosing all changes in membership.

On September 15, 2015, R Consortium filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on October 2, 2015 (80 FR 59815).

The last notification was filed with the Department on April 23, 2022. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on May 13, 2022 (87 FR 29384).

Suzanne Morris,

Deputy Director of Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023–01386 Filed 1–24–23; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc.**

Notice is hereby given that, on December 21, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”),

Subcutaneous Drug Development & Delivery Consortium, Inc. (“Subcutaneous Drug Development & Delivery Consortium, Inc.”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Biogen Inc., Cambridge, MA; C.H. Boehringer Sohn AG & Co. KG, Ridgefield, CT; Kaléo, Inc., Richmond, VA; KORU Medical Systems, Mahwah, NJ; NEMERA La Verpilliere SAS, La Verpilliere, FRANCE; and Comera Life Sciences, Woburn, MA, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership.

On October 26, 2020, Subcutaneous Drug Development & Delivery Consortium, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on December 3, 2020 (85 FR 78148).

The last notification was filed with the Department on April 25, 2022. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on May 13, 2022 (87 FR 29381).

Suzanne Morris,

Deputy Director of Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023–01371 Filed 1–24–23; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Bytecode Alliance Foundation**

Notice is hereby given that, on December 23, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Bytecode Alliance Foundation has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The

notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Docker, Inc., Palo Alto, CA; and Red Hat, Inc., Raleigh, NC, have been added as parties to this venture.

Also, EDJX, Inc., Raleigh, NC, has withdrawn as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Bytecode Alliance Foundation intends to file additional written notifications disclosing all changes in membership.

On April 20, 2022, Bytecode Alliance Foundation filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on May 13, 2022 (87 FR 29379).

The last notification was filed with the Department on October 17, 2022. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on November 8, 2022 (87 FR 67489).

Suzanne Morris,

Deputy Director of Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023–01370 Filed 1–24–23; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium**

Notice is hereby given that, on January 4, 2023, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Medical CBRN Defense Consortium (“MCDC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Foothold Labs, Inc., Olathe, KS; Luna Labs USA LLC, Charlottesville, VA; Molecular Technologies Laboratories LLC, Galena, OH; NUES, Inc., Silver Spring, MD; Schrodingier LLC, Portland, OR; and Sonogen Medical, Inc., Chevy Chase, MD, have been added as parties to this venture.